Potential use of liquid biopsy in diagnosing oral malignancies
Timbadiya Vijaykumar Mansukhbhai, Madhvika Patidar, Manjiri Chakor, Dakshayani Vijay Patil, Pawan Rebello, Gatha Mohanty, Rashmi Laddha
TL;DR
Liquid biopsy offers a non-invasive way to detect and monitor oral cancers by analyzing biomarkers in blood, but challenges remain in standardization and cost.
Contribution
The paper highlights the potential of liquid biopsy for early detection and monitoring of oral malignancies using ctDNA, CTCs, and exosomes.
Findings
Liquid biopsy shows good sensitivity and specificity for detecting mutations and biomarkers in oral squamous cell carcinoma.
Repeated sampling via liquid biopsy allows tracking of tumor burden and genetic changes over time.
Challenges include standardization, biomarker validation, and cost-effectiveness for clinical use.
Abstract
Liquid biopsy is a minimally invasive method with strong potential for detecting and monitoring oral cancers. By analyzing ctDNA, CTCs, exosomes and other tumor-derived biomarkers, it enables early detection, prognosis and treatment monitoring. Unlike tissue biopsy, it allows repeated sampling to track tumor burden and genetic changes over time. In oral squamous cell carcinoma, studies show good sensitivity and specificity for detecting mutations, methylation and protein markers. However, standardization, biomarker validation and cost-effectiveness remain challenges for clinical use.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHead and Neck Cancer Studies · Cancer Genomics and Diagnostics · Oral Health Pathology and Treatment